Anand Kumar, M.D. - Manitoba Health Sciences Centre
ROSII is a randomized, double-blinded controlled trial. The primary objective is to compare the antiviral efficacy of a 10 day course of standard and high-dose oseltamivir in the treatment of severe influenza infections. An important secondary objective of the trial is to determine the difference in the numbers of ventilator days between the standard-dose and high-dose groups.